Sepsis-induced Cardiomyopathy
Conditions
Interventions
Treatment group:Wenshen Yangxin Granules
Placebo group:placebo
Sponsors
Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Signing the informed consent form; (2) Meeting the diagnostic criteria for SIC; (3) Age between 18 and 80 years; (4) Patients admitted to the intensive care unit with an anticipated hospital stay of =7 days.
Exclusion criteria
Exclusion criteria: (1) Patients expected to die within 24 hours; (2) History of acute coronary syndrome, acute myocardial infarction diagnosis, or chronic heart failure; (3) Concomitant severe cardiac conditions such as valvular heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, etc.; (4) Postoperative patients after cardiac surgery in the last 2 months; (5) Suffering from severe primary diseases, including inoperable tumors, blood system disorders, and HIV infection; (6) Severe liver or kidney dysfunction (defined as liver or kidney component of SOFA score =3); (7) Received immunosuppressive agents or organ transplantation within the last 6 months; (8) Patients with allergies or hypersensitivity to Chinese herbal decoctions; (9) Pregnant or lactating women; (10) Participants in other clinical trials within the past 3 months; (11) Patients with contraindications to herbal decoction; (12) Other conditions considered inappropriate for participation by the clinical investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| all-cause mortality 28 days;28-day cardiac mortality;hospital mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| ICU mortality;ICU length of stay;hospital length of stay;change in Acute Physiology and Chronic Health Evaluation (APACHE) II score;change in the SOFA score;Echocardiogram;biomarker;hemodynamic parameters;central venous oxygen saturation;plasma lactate concentration;inflammatory markers;Utilization and Duration of Mechanical Circulatory Support;mechanical ventilation duration;CRRT usage;administration of vasopressors;administration of positive inotropic agents;Kansas City Cardiomyopathy Questionnaire (KCCQ-23) score; | — |
Countries
China
Contacts
Public ContactPeiyang Gao
Hospital of Chengdu University of Traditional Chinese Medicine
Outcome results
None listed